Full Year 2025 Revenues Increased 2% to $104.1 Million, the Highest Annual Revenues in Company History Company Updates Full Year 2026 Revenue Guidance Range to $109.0 Million to $111.0 Million, Representing 6% Year-Over-Year Growth at the Midpoint, and Updates Full Year 2026 Adjusted EBITDA Margin Guidance Range to 16% to 18%. ARR Expected to Increase from $95.4 Million at the Beginning of 2026 to Approximately $110.0 Million at the Beginning of 2027 FREMONT, Calif., March 03, 2026 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI) (“SoundThinking” or the “Company”), a leading public safety technology company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial and Operational HighlightsRevenues increased 6% to $24.8 million, compared to $23.4 million...

Eimskip has today published its audited consolidated financial statements for 2025. On 28 January 2026, Eimskip published a management financial report including the fourth quarter and full year 2025 results. In addition, Eimskip is publishing the Annual & sustainability report for 2025. The audited Consolidated financial statements can be found here: www.eimskip.com/2025/consolidated-financial-statements-2025 The Annual & Sustainability Report can be found here: https://www.eimskip.com/2025/annual-report-2025AttachmentsConsolidated Financial Statement 31.12.2025- Eimskipafélag Íslands hf549300IUR8Q7Y44KBL02-2025-12-31-1-en

YORK, Pa., March 03, 2026 (GLOBE NEWSWIRE) — The York Water Company’s (NASDAQ:YORW) President and CEO, JT Hand, announced the Company’s 2025 financial results. President Hand reported that 2025 operating revenues of $77,488,000 increased $2,529,000, but net income of $20,058,000 decreased $267,000 compared to 2024. Basic and Diluted Earnings per share of $1.39 for 2025 decreased $0.03 compared to 2024. Increased revenues were primarily due to growth in the customer base and revenues from the Distribution System Improvement Charge (DSIC). The DSIC is a Pennsylvania Public Utility Commission allowed charge that water utilities collect from customers for the replacement of aging infrastructure.   Income taxes decreased due to higher deductions from the IRS tangible property regulations. The Company also recognized a non-recurring...

GREENWICH, Conn., March 03, 2026 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended December 31, 2025.On February 26, 2026, our Board of Directors declared the following distributions on our common stock:Month Ending Record Date Payment Date Amount Per ShareApril 30, 2026 April 16, 2026 April 30, 2026 $0.035May 31, 2026 May 15, 2026 May 29, 2026 $0.035June 30, 2026 June 16, 2026 June 30, 2026 $0.035       Net asset value (“NAV”) per share as of December 31, 2025 stood at $1.69, compared with a NAV per share on September 30, 2025 of $1.95.Net investment income (“NII”) was approximately $5.4 million, or $0.07 per share, for the quarter ended...

— On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 — — Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment — — Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 — CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2025 and provided a business update. “We are shaping the future of genetic medicine by advancing a platform that is rapidly emerging as the predominant...

SPRINGFIELD, N.J., March 03, 2026 (GLOBE NEWSWIRE) — Village Super Market, Inc. (NSD-VLGEA) today reported its results of operations for the second quarter ended January 24, 2026. Second Quarter of Fiscal 2026 HighlightsNet income of $17.9 million, an increase of 6% compared to $16.9 million in the second quarter of the prior year Sales increased 6.9% and same store sales increased 4.8% Same store digital sales increased 15%Year-To-Date Fiscal 2026 HighlightsNet income of $29.9 million, an increase of 1% compared to $29.7 million in the prior year-to-date period Adjusted net income of $30.1 million, an increase of 1% compared to adjusted net income of $29.7 million in the prior year-to-date period Sales increased 5.7% and same store sales increased 3.7% Same store digital sales increased 15%Second Quarter of Fiscal 2026...

SINGAPORE, March 03, 2026 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha” or the “Company”) today announced its unaudited financial results for the fourth quarter and fiscal year ended December 2025. “Antalpha finished 2025 on a solid footing. As a crypto-native financing platform with tokenized gold upside, our Q4 revenue grew 110% from last year with increasing profitability. Our solid momentum throughout 2025, weathering Bitcoin’s volatility, reinforces Antalpha’s strategic positioning as a leading collateralized lending platform. We enable clients to navigate inherent Bitcoin volatility with strong risk management that reaps rewards for our clients and ultimately our shareholders,” said Paul Liang, CFO of Antalpha. “Our broader long-term product roadmap is to increase...

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026 Cash runway through 1Q 2027 PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “We are proud of the progress made in 2025 as we...

Total Q4 Revenues Increased 75% with Record Charging Network Revenue of $64 MillionInitiates 2026 guidance of $410 – $470 Million of Revenue and $(20) – $20 Million of Adjusted EBITDA1Total revenue of $118 million in the fourth quarter, representing an increase of 75% year-over-year. For the full year 2025, revenue reached $384 million, an increase of 50% over the full year 2024. Charging network revenue totaled a record $64 million in the fourth quarter, an increase of 37% year-over-year, representing the 16th consecutive quarter of double-digit year-over-year charging revenue growth. For the full year 2025, charging network revenue reached $218 million, an increase of 40% over the full year 2024. Network throughput reached 99 gigawatt-hours (“GWh”) in the fourth quarter, an increase of 18% year-over-year. Network throughput...

Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata’s organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA(1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million(2)NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) — Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons...